Press Releases

2017

December 18, 2017 Aduro Biotech Announces the Initiation of a Phase 1/2 Clinical Trial of BION-1301, a Novel Anti-APRIL Antibody, for the Treatment of Multiple Myeloma


December 12, 2017 Aduro Biotech Provides Update on CRS-207 Programs


December 11, 2017 Aduro Biotech to Host a Program Update Call


November 21, 2017 Aduro Biotech Scientific Advisor and Co-Founder of Aduro Biotech Europe Wiebe Olijve Honored with Royal Decoration


November 10, 2017 Aduro Biotech Announces Promising Preclinical Data that Validate Anti-CTLA-4 Antibody ADU-1604


November 01, 2017 Aduro Biotech Announces Upcoming Data Presentations at the 59th American Society of Hematology Annual Meeting


October 31, 2017 Aduro Biotech Reports Third Quarter 2017 Financial Results


October 17, 2017 Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung Cancer


October 09, 2017 Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting


September 27, 2017 Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology


September 26, 2017 Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas


September 18, 2017 Aduro Biotech to Present at Three Investor Conferences in the Second Half of September


August 31, 2017 Aduro Biotech to Present at Three Investor Conferences in the First Half of September


August 09, 2017 Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents


August 03, 2017 Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference


August 02, 2017 Aduro Biotech Reports Second Quarter 2017 Financial Results


July 27, 2017 Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific Officer Effective September 1, 2017


July 13, 2017 Aduro Announces Milestone Achieved Relating to Collaboration with Merck for Development of Anti-CD27 Antibody for the Treatment of Cancer


June 29, 2017 Aduro Biotech Announces Initiation of Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Previously-Treated Gastroesophageal Adenocarcinoma


June 28, 2017 Aduro Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of CRS-207 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Previously Treated Malignant Pleural Mesothelioma


June 01, 2017 Aduro Biotech Announces FDA Clearance of Investigational New Drug Application to Evaluate the Combination of ADU-S100 with PDR001 for the Treatment of Solid Tumors and Lymphomas


May 26, 2017 Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting


May 17, 2017 Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (Pembrolizumab) for the Treatment of Mesothelioma


May 02, 2017 Aduro Biotech Reports First Quarter 2017 Financial Results


April 25, 2017 Aduro Biotech to Present at Two Investor Conferences in May


April 20, 2017 Aduro Biotech Announces Management Promotions


March 15, 2017 Aduro Biotech to Host Research and Development Day in New York


March 10, 2017 Aduro Biotech Awarded East Bay Innovation Award for its Contributions in Life Sciences and the San Francisco East Bay Community


March 06, 2017 Aduro Biotech Announces Upcoming Data Presentations at the 2017 American Association for Cancer Research Annual Meeting


March 02, 2017 Aduro Biotech Announces Upcoming Data Presentations at the Keystone Symposia on Cancer Immunology and Immunotherapy Conference


March 01, 2017 Aduro Biotech Announces Fourth Quarter and Full Year 2016 Financial Results


February 28, 2017 Aduro Biotech to Present at Two Investor Conferences in March


February 10, 2017 Aduro Biotech to Present at the Leerink Partners 6th Annual Global Healthcare Conference


January 26, 2017 Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board


January 19, 2017 Aduro Biotech Enters into Exclusive License Agreement for Proprietary Neoantigen Identification Technology


January 09, 2017 Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer